Atara Biotherapeutics (ATRA) Accounts Payables (2013 - 2026)

Atara Biotherapeutics (ATRA) has reported Accounts Payables for 14 consecutive years, with $824000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accounts Payables fell 53.23% year-over-year to $824000.0; the trailing twelve-month figure through Jun 2026 stood at $824000.0 (down 53.23% YoY), and the FY2025 full-year result was $127000.0, down 97.09% from the prior year.
• Accounts Payables grew to $824000.0 in Q2 2026 per ATRA's latest filing, from $637000.0 in the prior quarter.
• Across five years, Accounts Payables topped out at $12.8 million in Q2 2022 and bottomed at $127000.0 in Q4 2025.
• Historically, Accounts Payables has averaged $4.6 million across 5 years, with a median of $3.9 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables grew 26.95% in 2024, then sank 97.09% in 2025.
• Over 5 years, Accounts Payables stood at $6.9 million in 2022, then slumped by 46.38% to $3.7 million in 2023, then rose by 18.54% to $4.4 million in 2024, then tumbled by 97.09% to $127000.0 in 2025, then soared by 548.82% to $824000.0 in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $824000.0, $637000.0, and $127000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.